Last reviewed · How we verify
Ivabradine Pill
Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, reducing heart rate without affecting blood pressure or contractility.
Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, reducing heart rate without affecting blood pressure or contractility. Used for Chronic heart failure with reduced ejection fraction (HFrEF) in patients with elevated resting heart rate, Stable angina pectoris.
At a glance
| Generic name | Ivabradine Pill |
|---|---|
| Sponsor | Tartu University Hospital |
| Drug class | If channel inhibitor |
| Target | HCN (hyperpolarization-activated cyclic nucleotide-gated) channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ivabradine works by blocking the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels responsible for the funny current in cardiac pacemaker cells. This selective inhibition slows the spontaneous depolarization of the sinoatrial node, thereby reducing heart rate. Unlike beta-blockers and calcium channel blockers, it does not affect myocardial contractility or atrioventricular conduction.
Approved indications
- Chronic heart failure with reduced ejection fraction (HFrEF) in patients with elevated heart rate
- Stable angina pectoris
Common side effects
- Bradycardia
- Phosphenes (visual symptoms with bright lights)
- Luminopsia
- Headache
- Dizziness
Key clinical trials
- Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit (PHASE4)
- Comparison Between Atenolol,Propnalol and Ivabradine (NA)
- PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery (PHASE4)
- Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (PHASE3)
- The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker (PHASE4)
- Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivabradine Pill CI brief — competitive landscape report
- Ivabradine Pill updates RSS · CI watch RSS
- Tartu University Hospital portfolio CI